{"organizations": [], "uuid": "8bc2f9cf61ffc914acb6975139fe1b7399bd0ffc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-amicus-therapeutics-announces-appr/brief-amicus-therapeutics-announces-approval-of-galafold-for-fabry-disease-in-japan-idUSFWN1R4145", "country": "US", "domain_rank": 408, "title": "BRIEF-‍Amicus Therapeutics Announces Approval Of Galafold For Fabry Disease In Japan​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-23T04:39:00.000+03:00", "replies_count": 0, "uuid": "8bc2f9cf61ffc914acb6975139fe1b7399bd0ffc"}, "author": "", "url": "https://www.reuters.com/article/brief-amicus-therapeutics-announces-appr/brief-amicus-therapeutics-announces-approval-of-galafold-for-fabry-disease-in-japan-idUSFWN1R4145", "ord_in_thread": 0, "title": "BRIEF-‍Amicus Therapeutics Announces Approval Of Galafold For Fabry Disease In Japan​", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "fabry disease in japan​ reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "amicus therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 23, 2018 / 1:40 AM / Updated 11 minutes ago BRIEF-‍Amicus Therapeutics Announces Approval Of Galafold For Fabry Disease In Japan​ Reuters Staff March 22 (Reuters) - Amicus Therapeutics Inc: * ‍AMICUS THERAPEUTICS ANNOUNCES APPROVAL OF GALAFOLD® (MIGALASTAT) FOR FABRY DISEASE IN JAPAN​ * ‍ANTICIPATES LAUNCHING GALAFOLD IN JAPAN IN COMING MONTHS​ * ‍WILL NOW PROCEED WITH PRICING AND REIMBURSEMENT PROCESSES​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-23T04:39:00.000+03:00", "crawled": "2018-03-23T04:59:42.039+03:00", "highlightTitle": ""}